CG
CYTK icon

Cutler Group’s Cytokinetics CYTK Stock Holding History

Cutler Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$113K Sell
8,600
-21,600
-72% -$1.67M 0.04% 417
2023
Q4 		$817K Buy
30,200
+22,400
+287% +$811K 0.07% 296
2023
Q3 		$11K Buy
7,800
+4,300
+123% +$143K ﹤0.01% 2408
2023
Q2 		$12K Buy
3,500
+1,100
+46% +$40.7K ﹤0.01% 2139
2023
Q1 		$2K Sell
2,400
-2,100
-47% -$85.7K ﹤0.01% 3114
2022
Q4 		$25K Buy
4,500
+2,400
+114% +$103K ﹤0.01% 2053
2022
Q3 		$30K Sell
2,100
-6,300
-75% -$303K ﹤0.01% 2297
2022
Q2 		$26K Buy
8,400
+3,300
+65% +$133K ﹤0.01% 2455
2022
Q1 		$25K Buy
5,100
+5,000
+5,000% +$178K ﹤0.01% 2846
2021
Q4 		$2K Sell
100
-13,300
-99% -$513K ﹤0.01% 4691
2021
Q3 		$39K Buy
+13,400
New +$395K ﹤0.01% 2719
2021
Q1 		– Sell
-500
Closed -$1K – 5736
2020
Q4 		$1K Buy
+500
New +$9.14K ﹤0.01% 4402
2020
Q3 		– Sell
-1,900
Closed -$9K – 4758
2020
Q2 		$9K Buy
+1,900
New +$35.6K ﹤0.01% 2930
2018
Q1 		– Sell
-4,800
Closed -$1K – 4583
2017
Q4 		$1K Sell
4,800
-31,900
-87% -$362K ﹤0.01% 4411
2017
Q3 		$67K Buy
36,700
+1,900
+5% +$26K ﹤0.01% 1979
2017
Q2 		$58K Buy
34,800
+15,600
+81% +$217K ﹤0.01% 2342
2017
Q1 		$39K Sell
19,200
-5,200
-21% -$60.8K ﹤0.01% 2647
2016
Q4 		$22K Buy
24,400
+2,600
+12% +$27.6K ﹤0.01% 3367
2016
Q3 		$13K Buy
21,800
+7,700
+55% +$80.4K ﹤0.01% 3883
2016
Q2 		$34K Sell
14,100
-5,800
-29% -$47.6K ﹤0.01% 2754
2016
Q1 		$11K Buy
19,900
+11,100
+126% +$81.1K ﹤0.01% 3942
2015
Q4 		$33K Buy
+8,800
New +$86.3K ﹤0.01% 2890

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cutler Group's CYTK Position: Q1 2024 in Review

Cutler Group opened a new position in Cytokinetics (CYTK) in Q1 2024: 603 shares worth $42K. The stake represents 0.01% of the portfolio and ranks #746 among its holdings. This is a return to the name: Cutler Group previously reported a position in CYTK as recently as Q3 2023.

Cutler Group first reported a position in CYTK in Q4 2015 and has held it in 22 quarters since. The position peaked at $526K in Q4 2016. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Cutler Group held 603 shares of Cytokinetics worth $42K as of Q1 2024.
  • Cytokinetics was a new Cutler Group position in Q1 2024.
  • Cytokinetics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #746 holding.
  • Cutler Group first reported a position in Cytokinetics in Q4 2015 and has held it in 22 quarters since.
  • Cutler Group's Cytokinetics position peaked at $526K in Q4 2016.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.